For the first time investigators are looking for patients to participate in a pivotal Phase 3 clinical trial of Pharnext’s lead investigational pleodrug, PXT-3003 for the potential treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A). The study which expects to enroll approximately 300 patients is taking place in the USA, Europe and Canada.
Nine of HNF’s Centers of Excellence are now accepting patients for trial enrollment. Please visit: www.hnf-cure.org/centersofexcellence to find out which centers in your area are recruiting and for contact information.
To learn about inclusion and exclusion criteria and for a complete list of sites visit: www.ClinicalTrials.gov and enter protocol # NCT02579759. Be sure to check back periodically as more sites are added, including Canada. BY GETTING INVOLVED YOU CAN HELP CHANGE THE FUTURE! Please consider signing up—and help us get the word out to others so they, too, can get involved. Together, let’s be a part of the first potential treatment for CMT!